Targeted oncology drugs · Drug development · Medical devices
HLB
A biotech advancing development of the targeted anticancer drug rivoceranib. KOSDAQ large-cap constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
Business categories Oncology & ADCs · Biopharma & Life Sciences · primary Pharmaceuticals & Biotechnology · Biopharma & Life Sciences
Other companies in the same category
- Oncology & ADCs: Bristol-Myers Squibb Company · Merck & Co. · LigaChem Biosciences · Daiichi Sankyo · Voronoi
- Pharmaceuticals & Biotechnology: Alnylam Pharmaceuticals · Regeneron Pharmaceuticals · Moderna · AbbVie · Lilly (Eli)
028300.KQ Updated Jul 11, 2026 4 AI consumers· 3 recurring
Annual return · 2026-09-04'21-29.6%'22+3.3%'23+134.2%'24+18.6%'25-31%YTD-39.2%
Money in ▸·
HLB
▸ Money out·
Financials & Segments
- Segments · Drug development (rivoceranib) · Medical devices and other
Revenue from
No refined links yet.
Pays to
No refined links yet.